NCT00464334View on ClinicalTrials.gov

A Study of V950 in People With Alzheimer Disease (V950-001 AM7)

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions
Alzheimer Disease
Interventions
BIOLOGICAL

V950

V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.

BIOLOGICAL

ISCOMATRIX™

ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.

BIOLOGICAL

Placebo to V950

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00464334 - A Study of V950 in People With Alzheimer Disease (V950-001 AM7) | Biotech Hunter | Biotech Hunter